A carregar...
Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome
BACKGROUND: Conventional therapies for hypereosinophilic syndromes (HES) have variable efficacy and carry significant long-term toxicities. Anti-IL-5 (mepolizumab) therapy has a glucocorticoid (GC)-sparing effect in GC-sensitive HES, but the efficacy of mepolizumab in treatment-refractory HES patien...
Na minha lista:
| Publicado no: | J Allergy Clin Immunol Pract |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6173586/ https://ncbi.nlm.nih.gov/pubmed/29751154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaip.2018.04.033 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|